HM17321
HM17321 is an experimental drug that acts as a corticotropin-releasing hormone receptor 2 (CRFR2) selective urocortin-2 (UCN2) analog developed by Hanmi Pharmaceutical.[1][2]
References
- ^ Kim, Jung Kuk; Lee, Seon Myeong; Kim, Eunseon; Lee, Dahae; Lee, Jieun; Kwon, Hyunjoo; Park, Eunjin; Kim, Jeong A.; Han, Seungsu; Park, Jongseo; Hong, Sunghee; Bae, Sungmin; Lee, Sang Hyun; Choi, In Young (20 June 2025). "843-P: A Novel CRFR2 Selective UCN2 Analog, HM17321, Facilitates Weight Loss and Improves Body Composition across Animal Models of Obesity". Diabetes. 74 (Supplement_1). doi:10.2337/db25-843-P.
- ^ "Hanmi's obesity drug that 'adds muscle while losing fat' wins FDA OK for phase 1". KBR. 6 November 2025. Retrieved 7 August 2026.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.